PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1334-1339

  Majewski, Ian J ^a   Nuciforo, Paolo ^b   Mittempergher, Lorenza ^a   Bosma, Astrid J ^a   Eidtmann, Holger ^d   Holmes, Eileen ^f   Sotiriou, Christos ^g   Fumagalli, Debora ^g   Jimenez, Jose ^b   Aura, Claudia ^b   Prudkin, Ludmila ^b   Díaz Delgado, Maria Carmen ^b   De la Peña, Lorena ^c   Loi, Sherene ^h   Ellis, Catherine ⁱ   Schultz, Nikolaus ^j   De Azambuja, Evandro ^g   Harbeck, Nadia ^e   Piccart Gebhart, Martine ^g   Bernards, René ^a   Baselga, José ^j   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c SOLTI Breast Cancer Research Group   (Spain)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^g JULES BORDET INSTITUTE   (Belgium)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ GLAXOSMITHKLINE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; ONCOGENE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMATIC MUTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NEOADJUVANT THERAPY; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84927620697     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2158     Document Type: Article

References (30)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
6. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
7. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
8. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501, 2002
9. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
10. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007
11. Dave B, Migliaccio I, Gutierrez MC, et al: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166-173, 2011
12. Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230, 2008
13. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, openlabel, multicentre, phase 3 trial. Lancet 379:633-640, 2012
14. de Azambuja E, Holmes AP, Piccart-Gebhart M, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO), a randomised, open-label, multicentre, phase 3 trial: Survival outcomes and their association with pathological complete response. Lancet Oncol 15:1137-1146, 2014
15. Majewski IJ, Mittempergher L, Davidson NM, et al: Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centered RNA sequencing. J Pathol 230:270-276, 2013
16. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
17. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
18. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
19. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
20. Baselga J, Cortes J, Im SA, et al: Biomarker analyses in CLEOPATRA: A phase III, placebocontrolled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 72:S5-1, 2012 (abstr)
21. Loibl S, Denkert C, Schneeweis A, et al: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer: Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Res 73:S4-06, 2013 (abstr)
22. Baselga J, Verma S, Ro J, et al: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Cancer Res 73:LB-63, 2013 (abstr)
23. Loi S, Michiels S, Lambrechts D, et al: Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105:960-967, 2013
24. Kalinsky K, Jacks LM, Heguy A, et al: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049-5059, 2009
25. Cizkova M, Susini A, Vacher S, et al: PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14:R28, 2012
26. Broad Institute: Broad GDAC. http://gdac.broadinstitute.org/
27. Krop IE, Saura C, Rodon Ahnert J, et al: A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. J Clin Oncol 30, 2012 (suppl; abstr 508)
28. Saura C, Bendell J, Jerusalem G, et al: PD09-03: Phase I/II study of BKM120 in combination with trastuzumab in patients with HER2 overexpressing metastatic breast cancer resistant to trastuzumab-containing therapy. Cancer Res 71:PD09-03, 2011 (abstr)
29. Juric D, Krop I, Ramanathan RK, et al: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Cancer Res 73:LB-64, 2013 (abstr)
30. Juric D, Rodon J, Gonzalez-Angulo AM, et al: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 72:CT-01, 2012 (abstr)